Related Experiment Video
Updated: Sep 24, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Head and Neck Squamous Cell Carcinoma: NT5E Could Be a Prognostic Biomarker
Yaoting Zhang1, Sultan Kadasah2, Jiaheng Xie3
1Department of Otorhinolaryngology-Head and Neck Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223300 Jiangsu, China.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is a type of tumour with a relatively poor prognosis. In recent years, immune checkpoint inhibitors, such as CTLA-4 and PD-1/PDL-1 inhibitors, have improved the treatment status of advanced tumours. However, the emergence of drug resistance has brought difficulties to clinical treatment, and new immune checkpoint research is imminent. The hypoxia-adenosine pathway, in which CD73 encoded by the NT5E gene is a key enzyme for adenosine production, has been identified as an immune checkpoint of great potential. Therefore, NT5E may play an important role in HNSCC. We performed a detailed bioinformatics analysis of NT5E in HNSCC, and the results showed that the overexpression of NT5E in HNSCC was associated with poor prognosis. Our further investigation of the coexpression pattern of HNSCC could provide a reference for drug resistance and immunotherapy studies.
Insights
Overexpression of the NT5E gene in head and neck squamous cell carcinoma (HNSCC) correlates with a poor prognosis. Targeting NT5E and its pathway may offer new strategies for overcoming immunotherapy resistance in HNSCC patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge with a generally poor prognosis.
- Advances in immunotherapy, including CTLA-4 and PD-1/PDL-1 inhibitors, have improved outcomes for advanced cancers, but drug resistance remains a hurdle.
- The hypoxia-adenosine pathway, involving CD73 (encoded by NT5E) as a key enzyme in adenosine production, is emerging as a critical immune checkpoint.
Purpose of the Study:
- To investigate the role of the NT5E gene in HNSCC.
- To analyze the prognostic significance of NT5E expression in HNSCC.
- To explore the potential of NT5E as a therapeutic target and its relevance to immunotherapy resistance.
Main Methods:
- Bioinformatic analysis of NT5E expression in HNSCC datasets.
- Correlation analysis between NT5E expression levels and patient prognosis.
- Investigation of NT5E coexpression patterns within the HNSCC tumor microenvironment.
Main Results:
- NT5E was found to be overexpressed in HNSCC tissues compared to normal tissues.
- Higher NT5E expression was significantly associated with poorer overall survival and clinical outcomes in HNSCC patients.
- Coexpression analysis revealed potential interactions of NT5E with other immune-related genes.
Conclusions:
- NT5E overexpression is a potential biomarker for poor prognosis in HNSCC.
- The NT5E-mediated hypoxia-adenosine pathway represents a promising target for novel immunotherapies in HNSCC.
- Understanding NT5E coexpression patterns may guide strategies to overcome drug resistance and enhance immunotherapy efficacy.
